Platelet transfusions are used in modern clinical practice both to prevent and treat bleeding in patients with low platelet counts due to bone marrow failure.

Stanworth S, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF

Published Online:

January 21, 2009

This review was undertaken to determine the best use of platelet transfusion for the prevention of bleeding (prophylactic platelet transfusion) in patients who have haematological malignancies and are receiving intensive chemotherapy or stem cell transplantation. The review aimed to look at two main topics. One, what is the evidence to indicate if platelet transfusions should be given to prevent bleeding as compared to a strategy aimed at transfusion when bleeding occurs? Second, if platelet transfusions are given to prevent bleeding, when should they be given, for example, at what level of platelet count when measured in a blood sample? The reviewers found that there is uncertainty about the practice of prophylactic transfusion therapy. New studies may be needed to better answer these two questions, particularly in view of concerns about the safety and cost of blood and the scenario that blood products, including platelets, could become an increasingly scarce resource in the future.

Abstract (click to read)

Background:

Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in thrombocytopenic patients with bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 30 years, some areas continue to provoke debate especially the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding.

Objectives:

To determine the optimal use of platelet transfusion for the prevention of haemorrhage (prophylactic platelet transfusion) in patients with haematological malignancies undergoing chemotherapy or stem cell transplantation.

Search strategy:

Randomised controlled trials (RCTs) were searched for in the Cochrane Central Register of Controlled Trials (CENTRAL). Searching was also undertaken on the OVID versions of MEDLINE and EMBASE using an RCT search filter strategy.

Selection criteria:

Randomised controlled trials involving transfusions of platelet concentrates, prepared either from individual units of whole blood or by apheresis, and given prophylactically to prevent bleeding in patients with haematological malignancies.

Data collection and analysis:

All electronically derived citations and abstracts of papers, identified by the review search strategy, were initially screened for relevancy by one reviewer. The full text of all potentially relevant trials was then formally assessed for eligibility by two reviewers independently. Two reviewers completed data extraction independently. Missing data were requested from the original investigators, as appropriate.

Main results:

Eight completed published trials, with a total of 390 participants in the intervention groups and 362 participants in the control groups, were included for analysis in the review.
The eight studies were classified as:

three trials relevant to prophylactic platelet transfusions versus therapeutic platelet transfusions;
three trials relevant to prophylactic platelet transfusion with one trigger level versus prophylactic platelet transfusion with another trigger level;
two trials relevant to prophylactic platelet transfusion with one dose schedule versus prophylactic platelet transfusion with another dose schedule.

The few reports of controlled trials addressing prophylactic versus therapeutic transfusions contained small numbers of patients and were all undertaken over 25 years ago. None of the studies explicitly clarified whether the lack of a reported difference was a reflection of insufficient power in the trials. The findings of the meta-analyses for this group of three small studies must be interpreted with caution.
In contrast, more contemporary trials addressed the question of what platelet count thresholds should apply for prophylactic transfusion; three identified studies broadly compared platelet transfusion thresholds of 10 versus 20 x 109/litre for different clinical groups of patients. There were no statistically significant differences between the groups with regards to mortality, remission rates, number of participants with severe bleeding events or red cell transfusion requirements. However, it was unclear whether the studies had sufficient power to demonstrate in combination non-inferiority in terms of safety of the lower threshold, 10x109/litre.
Insufficient randomised trials have been undertaken to make clinically relevant conclusions about the effect of different platelet doses.

Authors' conclusions:

There are no reasons to change current practice, but uncertainty about the practice of prophylactic transfusion therapy should be recognised, particularly in the light of concerns about the scenario that blood products including platelets could become an increasingly scarce resource in the future and for which adequate alternatives do not exist. Consideration should be given to developing adequately powered trials comparing strategies of prophylaxis versus therapeutic platelet transfusion.

This record should be cited as:

Stanworth S, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004269. DOI: 10.1002/14651858.CD004269.pub2

Assessed as up to date:

July 27, 2004

Find the research

Get full text at The Cochrane Library

Primary Review Group:

Haematological Malignancies Group

Health topics:

Blood disorders > Haematological malignancies > Supportive care

Cancer > Haematological malignancies > Supportive care

Cochrane Summaries^beta

Independent high-quality evidence for health care decision making

Platelet transfusions are used in modern clinical practice both to prevent and treat bleeding in patients with low platelet counts due to bone marrow failure.

More like this

Copyright © 2011 - The Cochrane Collaboration